Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3021 intravitreal injection for geographic atrophy secondary to age-related macular degeneration (Japan)
jRCT2031250086Phase 4Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2025
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of avacincaptad pegol in age-related macular degeneration (AMD), sponsored by Astellas Pharma. Primary endpoint: Frequency and severity of treatment-emergent adverse events (TEAEs) and serious TEAEs. Started Jul 2025; status: active, not recruiting.
02
Drugs
avacincaptad pegol
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on jRCT2031250086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250086.